Balanced news tone
News Sentiment
BLTE sentiment intelligence
Belite Bio Inc ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+1.8% over one week, +8.1% over four weeks, trend inactive, and materially above fair value.
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Stock Titan
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 16 Jun 2026 07:00
- Source
- Investing.com
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 01:30
- Source
- GlobeNewswire
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 12 Jun 2026 07:00
- Source
- Market source
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 12:00
- Source
- GlobeNewswire
Goldman Sachs healthcare conference to host Belite Bio fireside chat June 8
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Stock Titan
Belite Bio, Inc (BLTE) Presents at 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - Slideshow (NASDAQ:BLTE) 2026-05-27
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Seeking Alpha
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 26 May 2026 10:27
- Source
- MT Newswires
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 May 2026 05:00
- Source
- GuruFocus.com
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE)
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 20 May 2026 07:00
- Source
- Market source
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- GlobeNewswire
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Investing.com
Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA Submission
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
When Can We Expect A Profit From Belite Bio, Inc (NASDAQ:BLTE)?
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 13 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Stock Titan
BELITE BIO ($BLTE) Releases Q4 2025 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Mar 2026 08:00
- Source
- Quiver Quantitative